Generic Drugs

Approval granted to market Glimepiride; Vogseal launched in Japan

Published in Obesity and Diabetes Week, August 22nd, 2005

Ranbaxy Laboratories Limited (RLL) announced that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Glimepiride Tablets, 1 mg, 2 mg, 4 mg, and 8 mg.

Total annual market sales for Glimepiride were $336.6 million (+22.4%) (IMS - MAT: March 2005).

Glimepiride is indicated as an adjunct to diet and exercise, to lower the blood glucose in patients with noninsulin-dependent (type II) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone.

The product may be used concomitantly with Metformin when diet, exercise, and Glimepiride or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry